BLUE bluebird bio Inc.

105.37
-2.07  -2%
Previous Close 107.44
Open 108.31
Price To Book 3.56
Market Cap 5,823,719,713
Shares 55,269,239
Volume 99,576
Short Ratio
Av. Daily Volume 551,655

NewsSee all news

  1. bluebird bio Presents Updated Data from Phase 2/3 Clinical Study of Lenti-D™ Gene Therapy for Cerebral Adrenoleukodystrophy (CALD) at the 13th European Pediatric Neurology Society (EPNS) Congress

    Long-Term Follow-up Data Show That the 88% of Patients Treated in the Starbeam Study (ALD-102) Were Free of Major Functional Disabilities (MFDs) at Two Years, and Continued to Remain MFD-Free at up to Five Years of

  2. bluebird bio to Present Data from Clinical Development Program of Lenti-DTM Gene Therapy for Cerebral Adrenoleukodystrophy (CALD) at the 13th European Pediatric Neurology Society (EPNS) Congress

    Data Include Updates from Phase 2/3 Starbeam Study (ALD-102) of Lenti-D for CALD and Ongoing Observational Study (ALD-103) of Allogeneic Hematopoietic Stem Cell Transplant for CALD bluebird bio, Inc. (NASDAQ:BLUE)

  3. bluebird bio Announces Investor Events in September

    bluebird bio, Inc. (NASDAQ:BLUE) today announced that members of the management team will present at the following upcoming investor conferences in September: Citi 14th Annual Biotech Conference, Wednesday, September

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial to be initiated in 2019.
LentiGlobin - HGB-210
Sickle Cell Disease (SCD)
Phase 3 presentation of data by end of 2019.
LentiGlobin - HGB-212 Northstar-3
TDT and the β0/β0genotype
Phase 2 data due by the end of 2019.
bb2121 - KarMMa
Relapsed/refractory multiple myeloma
Phase 3 presentation of data by end of 2019.
LentiGlobin - HGB-207 Northstar-2
non-β0/β0 transfusion-dependent thalassemia (TDT)
Phase 2/3 updated data September 18, 2019 noted 88% (N=15/17) continue to be alive and MFD-free.
Lenti-D - Starbeam
Childhood cerebral adrenoleukodystrophy (CCALD)
Updated data due at EHA June 14, 2019 noted 3.8 years of transfusion independence in patients who do not have a β0/β0 genotype.
LentiGlobin - HGB-204
β-Thalassemia
Phase 1/2 presentation of data by end of 2019.
LentiGlobin - HGB-206
Sickle disease
Phase 1 data due by the end of 2019.
bb21217
Multiple Myeloma

Latest News

  1. bluebird bio Presents Updated Data from Phase 2/3 Clinical Study of Lenti-D™ Gene Therapy for Cerebral Adrenoleukodystrophy (CALD) at the 13th European Pediatric Neurology Society (EPNS) Congress

    Long-Term Follow-up Data Show That the 88% of Patients Treated in the Starbeam Study (ALD-102) Were Free of Major Functional Disabilities (MFDs) at Two Years, and Continued to Remain MFD-Free at up to Five Years of

  2. bluebird bio to Present Data from Clinical Development Program of Lenti-DTM Gene Therapy for Cerebral Adrenoleukodystrophy (CALD) at the 13th European Pediatric Neurology Society (EPNS) Congress

    Data Include Updates from Phase 2/3 Starbeam Study (ALD-102) of Lenti-D for CALD and Ongoing Observational Study (ALD-103) of Allogeneic Hematopoietic Stem Cell Transplant for CALD bluebird bio, Inc. (NASDAQ:BLUE)

  3. bluebird bio Announces Investor Events in September

    bluebird bio, Inc. (NASDAQ:BLUE) today announced that members of the management team will present at the following upcoming investor conferences in September: Citi 14th Annual Biotech Conference, Wednesday, September